We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vindon H. | LSE:VDN | London | Ordinary Share | GB00B06N4S86 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 13.25 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 13.25 | GBX |
Vindon Healthcare (VDN) Share Charts1 Year Vindon Healthcare Chart |
|
1 Month Vindon Healthcare Chart |
Intraday Vindon Healthcare Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/7/2015 | 16:40 | Vindon Healthcare - Preserving in Space | 278 |
| 22/10/2009 | 09:37 | Vindon Healthcare | 77 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 31/10/2013 22:22 by buywell2 SBS now trading at 10.75pSellers of VDN stock that ploughed their cash into SBS shares would have done OK it seems |
Posted at 18/9/2013 17:18 by piedro The 'squeeze' ....OFFER CLOSING FOR FURTHER ACCEPTANCES AND COMPULSORY ACQUISITION OF VINDON SHARES On 17 September 2013, Source BioScience announced that its recommended cash offer to acquire the entire issued and to be issued share capital of Vindon had been declared unconditional in all respects. Source BioScience today announces that the Offer will be closed to further acceptances with effect from 2 October 2013. Source BioScience has today implemented the procedure under Chapter 3 of Part 28 of the Companies Act 2006 to compulsorily acquire all of the outstanding Vindon Shares which it does not already hold or has not already acquired, contracted to acquire or in respect of which it has not already received valid acceptances. Letters have been sent to non-assenting Vindon Shareholders informing them of the intended exercise by Source BioScience of its right under section 979 of the Companies Act 2006 (the "Act") to 'squeeze-out' such Vindon Shareholders, together with a notice of such action pursuant to section 980(1) of the Act. Settlement of the consideration to which any Vindon Shareholders (or, in the absence of any contrary direction as specified in the Offer Document, the first named shareholder in the case of joint shareholders) are entitled under the Offer will be effected (in the manner set out in paragraph 20 of Part II of the Offer Document): (i) in the case of acceptances received on or before 13 September 2013, complete in all respects, by 27 September 2013 or, (ii) in the case of acceptances received, complete in all respects, after 13 September 2013 but on or before 2 October 2013, within 14 days of such receipt. Non-assenting shareholders who do not accept the Offer by 2 October 2013 will not receive payment until after compulsory purchase has been implemented on 30 October 2013. ... |
Posted at 02/9/2013 11:47 by piedro Mr Yeung Yu Loong has now increased his SBS holding to 5.55%Any VDN holders or ex-holders have any comments on Source BioSciences. |
Posted at 29/8/2013 08:46 by buywell2 '' Source BioScience said its 13.7p a share offer for Vindon Healthcare had received valid acceptances totalling 82.9% of that company's issued share capital. It extended its offer to Sept. 11 ''Source Bioscience H1 pretax profit rises to £0.6m 29 August 2013 | 08:14am Source Bioscience's first-half pretax profit rises to £0.6 million, from £0.4 million. Revenue rose to £8.8 million, from £8.4 million. "The encouraging first half of the year represents a continuation of the strong growth and business performance achieved last year and reflects the substantial opportunities we see for further development across both our Healthcare and LifeSciences divisions," said chairman Laurie Turnbull in a statement. Separately, Source BioScience said its 13.7p a share offer for Vindon Healthcare had received valid acceptances totalling 82.9% of that company's issued share capital. It extended its offer to Sept. 11. www.stockmarketwire. |
Posted at 29/8/2013 07:45 by buywell2 Vindon is going to belong to Source BioScience PiedroThat you have most likely lost money on your investment is not my fault and is no excuse for being rude What you have to decide is whether you want to become a SBS shareholder, if you believe enough in the Vindon story that you have written here on advfn thus far that you still want to carry on with it albeit under another name but still with the VDN CEO on the board Check out SBS results today |
Posted at 22/8/2013 07:29 by buywell2 Have you sold your VDN shares Piedro yet ? |
Posted at 19/8/2013 12:20 by piedro Re: Ian YeungThank you for the confirmation Those 8.5m shares give more weight to his arguments Certainly the share price has taken a tumble since the offer. 8p/share would be interesting. |
Posted at 15/8/2013 11:49 by piedro Thank you, Mr. Yeung was of the opposition note then.He does make some interesting points which are well worth being considered by SBS shareholders - IMHO In the offer document (downloadable from the VDN website) it is stated that SBS intends to continue with Vindon's current activities and that their places of business and fixed assets will remain unchanged. Also most of Vindon's directors and senior management will remain in the enlarged group As Mr. Yeung points out, this will change the nature of SBS and suggest to me that perhaps they also are struggling to find their niche |
Posted at 12/8/2013 16:00 by piedro Article in the ShareSoc Informerre: Source BioScience offer for VDN hxxp://www.sharesoc. ... you may need to register to read the article (free) ... not everyone is in agreement |
Posted at 16/7/2013 09:55 by buywell2 You have been ploughing a lone furrow for many years PiedroYour hard work has not gone unnoticed Welcome to the SBS fold My take is that with SBS using VDN storage facilities in the USA , and Ireland to sell SBS Life Sciences products , antibodies/clones/re www.sourcebioscience Also SBS have been expanding their DNA sequencing services at a pace , profits up circa 50% from this year on year .... they can now do the same from the two USA VDN bases and thus tap into the BIGGEST Pharma Biotech CRO area in the WORLD. Plus cross selling opportunities to each others Client Lists means the 'Collective' after assimilation should be more than the sum of each of the individuals within 12 months. Vindon will be the 5th SBS acquisition ..... Turnover for the first 6 months announced next month should be UP 30%. They are going places ..... check out the recent Institutional holdings taken in the company in the last 12 to 18 months. Some BIG names have bought in Major Shareholders holding over 3% ... Shares in issue :203.8m 2p Ords Name .................... TD Direct Investing (Europe) 21,000,000 ....10.0 Henderson Global Investors .. 12,095,215 ..... 5.9 Mr S Varkey .................. 3,522,581 ..... 1.73 Seren Capital Manag't ....... 10,675,000 ..... 6.6 SBS Directors/Snr Manag't ....14,222,897 ..... 7.38 Killik & Co LLP ............. 10,586,131 ..... 5.20 Blackrock Inv't Manag't ..... 10,715,000 ..... 5.26 Legal & Gen Assurance ....... 16,637,876 ..... 8.16 Barclays Bank Plc (Pvte Bing) 9,300,000 ...... 4.2 Standard Life Investments .... 9,500,000 ..... 4.66 Mr Yeung Yu Loong ........... 8,528,228 ...... 4.16 Swedbank Robur .............. 6,000,000 ...... 2.94 Talos Securities Ltd. ....... 5,900,000 ...... 2.9% 69% Per cent of shares held by top holders Source BioScience makes a strong start to the year 12 June 2013 | 14:47pm StockMarketWire.com - Source BioScience, which reported further growth and increased profitability in 2012, has made a good start to this year. Laurie Turnbull, chairman, told today's AGM: "Demand from the NHS for our diagnostic services continues to be strong and year to date revenue has increased by over 35% compared with the same period last year. "We remain one of only a small number of accredited laboratories in Europe with access to the technologies and expertise required to deliver complex gene-based diagnostic testing for cancer and other diseases, which affords us commercial advantage." Mr Turnbull also commented that the company enjoyed a leading position in the UK for the provision of DNA sequencing services and remain the only company offering a UK-based sequencing service. He added: "This part of our business will be boosted by the expansion of our service into Scotland, enabling us to offer our overnight service for DNA sequencing to the local research community. Hope this sits well Bro |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
